SCHEMBL4094869

SCHEMBL4094869

CCN(CC)CCOc1cc(-c2nc(Cl)nc3[nH]cnc23)c(Cl)cc1C

nearest known ligand 0.46

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
HSP90AB1 P08238 7/20 0.46
KCNH2 Q12809 4/20 0.46
HSP90AA1 P07900 2/20 0.39
CYP2C19 P33261 1/20 0.39
KDM4E B2RXH2 1/20 0.36
AGER Q15109 1/20 0.34
SIGMAR1 Q99720 1/20 0.33
EGFR P00533 3/20 0.33
KDR P35968 3/20 0.33
BIRC5 O15392 1/20 0.32
ACHE P22303 1/20 0.31
ALDH1A1 P00352 1/20 0.31
POLB P06746 1/20 0.31
GAA P10253 1/20 0.31
NPSR1 Q6W5P4 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4091000 0.93 HSP90AB1 (0.51) HSP90AB1KCNH2HSP90AA1CYP2C19KDM4E
SCHEMBL4089936 0.88 HSP90AB1 (0.60) HSP90AB1KCNH2HSP90AA1CYP2C19KDM4E
SCHEMBL4258574 0.81 HSP90AB1 (0.56) HSP90AB1KCNH2HSP90AA1CYP2C19POLB
SCHEMBL4258586 0.80 HSP90AB1 (0.48) HSP90AB1KCNH2HSP90AA1CYP2C19EGFR
SCHEMBL4098709 0.79 HSP90AB1 (0.44) HSP90AB1KCNH2HSP90AA1CYP2C19KDM4E
SCHEMBL4101361 0.76 CCR5 (0.37) HSP90AB1KCNH2HSP90AA1CYP2C19
SCHEMBL4259002 0.75 XDH (0.32) HSP90AB1CYP2C19KDM4EKDRALDH1A1
SCHEMBL4094713 0.71 HSP90AB1 (0.51) HSP90AB1KCNH2HSP90AA1KDM4EKDR
SCHEMBL14567303 0.70 HSP90AB1 (0.36) HSP90AB1KCNH2HSP90AA1CYP2C19
SCHEMBL4102915 0.70 YTHDC1 (0.49) HSP90AB1KCNH2HSP90AA1CYP2C19ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090181989-A1 Purine Compunds as HSP90 Protein Inhibitors for the Treatment of Cancer VERNALIS ( R & D) LTD. (GB) 2009-07-16 US disclosed
US-20090181989-A1 Purine Compunds as HSP90 Protein Inhibitors for the Treatment of Cancer VERNALIS ( R & D) LTD. (GB) 2009-07-16 US disclosed
US-20090181989-A1 Purine Compunds as HSP90 Protein Inhibitors for the Treatment of Cancer VERNALIS ( R & D) LTD. (GB) 2009-07-16 US disclosed
EP-2004648-A1 PURINE COMPOUNDS AS HSP90 PROTEIN INHIBITORS FOR THE TREATMENT OF CANCER Vernalis (R&D) Limited (GB) 2008-12-24 EP disclosed
WO-2007034185-A1 PURINE COMPOUNDS AS HSP90 PROTEIN INHIBITORS FOR THE TREATMENT OF CANCER VERNALIS (R & D) LTD. (GB) 2007-03-29 WO disclosed
WO-2007034185-A1 PURINE COMPOUNDS AS HSP90 PROTEIN INHIBITORS FOR THE TREATMENT OF CANCER VERNALIS (R & D) LTD. (GB) 2007-03-29 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090181989-A1 Purine Compunds as HSP90 Protein Inhibitors for the Treatment of Cancer HSP90AA1, HSP90AB1, HSP90AB2P HSP90AB1 2/4885KCNH2 3508/4885HSP90AA1 1/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.